VANGUARD GROUP INC 13D and 13G filings for Arrowhead Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-04-10 2:03 pm Purchase | 2024-03-28 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | VANGUARD GROUP INC | 12,404,050 10.010% | 1,731,974 (+16.23%) | Filing |
| 2024-02-13 4:58 pm Sale | 2023-12-29 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | VANGUARD GROUP INC | 10,672,076 9.930% | -158,357 (-1.46%) | Filing |
| 2023-06-09 2:15 pm Purchase | 2023-05-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | VANGUARD GROUP INC | 10,830,433 10.130% | 544,261 (+5.29%) | Filing |
| 2023-02-09 11:07 am Purchase | 2022-12-30 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | VANGUARD GROUP INC | 10,286,172 9.700% | 646,029 (+6.70%) | Filing |
| 2022-02-09 3:24 pm Purchase | 2021-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | VANGUARD GROUP INC | 9,640,143 9.220% | 358,592 (+3.86%) | Filing |
| 2021-02-10 10:30 am Sale | 2020-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | VANGUARD GROUP INC | 9,281,551 9.030% | -515,956 (-5.27%) | Filing |